Eli Lilly and Company's cholesterol medication evacetrapib, discontinued in a large trial back in October, did not reduce major cardiovascular events like stroke and heart attack. This was discovered recently by researchers who, for the first time, saw the data behind the discontinuation of the trial.
Eli Lilly and Company's cholesterol medication evacetrapib, discontinued in a large trial back in October, did not reduce major cardiovascular events like stroke and heart attack. This was discovered recently by researchers who, for the first time, saw the data behind the discontinuation of the trial.
Share this Article
Recommended